ORIC Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 107905 min ago

@ $11.31

Išleistas: 14 vas. 2024 @ 21:07

Grąža: -25.90%

Ankstesnis signalas: vas. 13 - 20:45

Ankstesnis signalas: Pardavimas

Grąža: -1.65 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 20:32):

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States...

Stats
Šios dienos apimtis	184 690
Vidutinė apimtis	570 877
Rinkos kapitalizacija	565.00M
EPS	$0 ( 2024-03-21 )
Kita pelno data	( $-0.440 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.28
ATR14	$0.0170 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-06	Chacko Jacob	Sell	40 000	Common Stock
2024-02-06	Chacko Jacob	Sell	13 958	Common Stock
2024-02-07	Chacko Jacob	Sell	26 042	Common Stock
2024-01-02	Multani Pratik S	Buy	180 000	Stock Option (right to buy)
2024-01-02	Multani Pratik S	Buy	30 000	Restricted Stock Unit

INSIDER POWER
54.58
Last 99 transactions
Buy: 6 373 472 \| Sell: 3 807 004

Tūris Koreliacija

Ilgas: 0.12 (neutral)

Trumpas: 0.09 (neutral)

Signal:(32.364) Neutral

Oric Pharmaceuticals Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Oric Pharmaceuticals Inc Koreliacija - Valiuta/Žaliavos

0.87
( strong )

0.88
( strong )

0.00
( neutral )

0.77
( moderate )

0.79
( moderate )

-0.65
( weak negative )

Oric Pharmaceuticals Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-1.03M (0.00 %)
EPS:	$-1.960

FY	2023
Pajamos:	$0
Bruto pelnas:	$-1.03M (0.00 %)
EPS:	$-1.960

FY	2022
Pajamos:	$0
Bruto pelnas:	$-966 000 (0.00 %)
EPS:	$-2.31

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.07

Financial Reports:

No articles found.

Oric Pharmaceuticals Inc

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.